Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 5/2011

01-05-2011 | Original paper

Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can)

Authors: Martin Almquist, Dorthe Johansen, Tone Björge, Hanno Ulmer, Björn Lindkvist, Tanja Stocks, Göran Hallmans, Anders Engeland, Kilian Rapp, Håkan Jonsson, Randi Selmer, Guenter Diem, Christel Häggström, Steinar Tretli, Pär Stattin, Jonas Manjer

Published in: Cancer Causes & Control | Issue 5/2011

Login to get access

Abstract

Objective

To investigate metabolic factors and their possible impact on risk of thyroid cancer.

Methods

A prospective cohort study was conducted based on seven population-based cohorts in Norway, Austria, and Sweden, in the Metabolic syndrome and Cancer project (Me-Can). Altogether 578,700 men and women with a mean age of 44.0 years at baseline were followed for on average 12.0 years. Relative risk of incident thyroid cancer was assessed by levels of BMI, blood pressure, and blood levels of glucose, cholesterol, triglycerides, and by a combined metabolic syndrome (MetS) score. Risk estimates were investigated for quintiles, and a z score distribution of exposures was analyzed using Cox proportional hazards regression.

Results

During follow-up, 255 women and 133 men were diagnosed with thyroid cancer. In women, there was an inverse association between glucose and thyroid cancer risk, with adjusted RR: 95% CI was 0.61 (0.41–0.90), p trend = 0.02 in the fifth versus the first quintile, and a positive association between BMI and thyroid cancer risk with a significant trend over quintiles. There was no association between the other metabolic factors, single or combined (Met-S), and thyroid cancer.

Conclusion

In women, BMI was positively, while blood glucose levels were inversely, associated with thyroid cancer.
Literature
1.
Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. Jama 295:2164–2167PubMedCrossRef
2.
Iribarren C, Haselkorn T, Tekawa IS, Friedman GD (2001) Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 93:745–750PubMedCrossRef
3.
Dal Maso L, La Vecchia C, Franceschi S et al (2000) A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control 11:137–144PubMedCrossRef
4.
Reaven GM (1997) Banting lecture 1988. Role of insulin resistance in human disease. Nutrition 13:65 discussion 64, 66
5.
Daskalopoulou SS, Athyros VG, Kolovou GD, Anagnostopoulou KK, Mikhailidis DP (2006) Definitions of metabolic syndrome: where are we now? Curr Vasc Pharmacol 4:185–197PubMedCrossRef
6.
Hu G, Qiao Q, Tuomilehto J (2005) The metabolic syndrome and cardiovascular risk. Curr Diabetes Rev 1:137–143PubMedCrossRef
7.
Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR (2006) The metabolic syndrome and risk of incident colorectal cancer. Cancer 107:28–36PubMedCrossRef
8.
Lund Haheim L, Wisloff TF, Holme I, Nafstad P (2006) Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 164:769–774PubMedCrossRef
9.
Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L (1997) Risk factors for malignant diseases: a cohort study on a population of 22, 946 Icelanders. Cancer Epidemiol Biomarkers Prev 6:863–873PubMed
10.
Stocks T, Borena W, Strohmaier S et al (2010) Cohort profile: the metabolic syndrome and cancer project (Me-Can). Int J Epidemiol 39:660–667PubMedCrossRef
11.
Rapp K, Schroeder J, Klenk J et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49:945–952PubMedCrossRef
12.
Leren P, Askevold EM, Foss OP et al (1975) The Oslo study. Cardiovascular disease in middle-aged and young Oslo men. Acta Med Scand Suppl 588:1–38PubMed
13.
Bjartveit K, Foss OP, Gjervig T (1983) The cardiovascular disease study in Norwegian counties. Results from first screening. Acta Med Scand Suppl 675:1–184PubMed
14.
Naess O, Sogaard AJ, Arnesen E et al (2008) Cohort profile: cohort of Norway (CONOR). Int J Epidemiol 37:481–485PubMedCrossRef
15.
Aires N, Selmer R, Thelle D (2003) The validity of self-reported leisure time physical activity, and its relationship to serum cholesterol, blood pressure and body mass index. A population based study of 332, 182 men and women aged 40–42 years. Eur J Epidemiol 18:479–485PubMedCrossRef
16.
Lindahl B, Weinehall L, Asplund K, Hallmans G (1999) Screening for impaired glucose tolerance. Results from a population-based study in 21, 057 individuals. Diabetes Care 22:1988–1992PubMedCrossRef
17.
Berglund G, Eriksson KF, Israelsson B et al (1996) Cardiovascular risk groups and mortality in an urban swedish male population: the Malmo preventive project. J Intern Med 239:489–497PubMedCrossRef
18.
Bjartveit K, Foss OP, Gjervig T, Lund-Larsen PG (1979) The cardiovascular disease study in Norwegian counties. Background and organization. Acta Med Scand Suppl 634:1–70PubMed
19.
Percy C, Van Holten V, Muir C (eds) (1990) International classification of diseases for oncology. World Health Organization, Geneva
20.
21.
Fibrinogen Studies Collaboration (2009) Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. Stat Med 28:1067–1092CrossRef
22.
Clarke R, Shipley M, Lewington S et al (1999) Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341–353PubMed
23.
Wood AM, White I, Thompson SG, Lewington S, Danesh J (2006) Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol 35:1570–1578PubMedCrossRef
24.
Jee SH, Ohrr H, Sull JW et al (2005) Fasting serum glucose level and cancer risk in Korean men and women. Jama 293:194–202PubMedCrossRef
25.
Stattin P, Björ O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30:7CrossRef
26.
Stocks T, Rapp K, Bjorge T et al (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6:e1000201PubMedCrossRef
27.
Zhan YS, Feng L, Tang SH et al (2010) Glucose metabolism disorders in cancer patients in a Chinese population. Med Oncol 27:177–184PubMedCrossRef
28.
Zivaljevic V, Vlajinac H, Jankovic R et al (2004) Case-control study of anaplastic thyroid cancer. Tumori 90:9–12PubMed
29.
Randi G, Ferraroni M, Talamini R et al (2008) Glycemic index, glycemic load and thyroid cancer risk. Ann Oncol 19:380–383PubMedCrossRef
30.
Clavel-Chapelon F, Guillas G, Tondeur L, Kernaleguen C, Boutron-Ruault MC (2010) Risk of differentiated thyroid cancer in relation to adult weight, height, and body shape over life: the French E3 N cohort. Int J Cancer 126:2984–2990PubMed
31.
Engeland A, Tretli S, Akslen LA, Bjorge T (2006) Body size and thyroid cancer in two million Norwegian men and women. Br J Cancer 95:366–370PubMedCrossRef
32.
Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish cancer register: a sample survey for year 1998. Acta Oncol 48:27–33PubMedCrossRef
33.
Larsen IK, Smastuen M, Johannesen TB et al (2009) Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 45:1218–1231PubMedCrossRef
34.
Fiore E, Rago T, Provenzale MA et al (2009) Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer 16:1251–1260PubMedCrossRef
35.
Ayturk S, Gursoy A, Kut A et al (2009) Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. Eur J Endocrinol 161:599–605PubMedCrossRef
36.
Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH (2007) Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 92:491–496PubMedCrossRef
37.
Garduno-Garcia Jde J, Alvirde-Garcia U, Lopez-Carrasco G et al (2010) TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol 163:273–278
38.
Negri E, Dal Maso L, Ron E et al (1999) A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control 10:143–155PubMedCrossRef
39.
La Vecchia C, Ron E, Franceschi S et al (1999) A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 10:157–166PubMedCrossRef
40.
Saad F, Gooren L (2009) The role of testosterone in the metabolic syndrome: a review. J Steroid Biochem Mol Biol 114:40–43PubMedCrossRef
41.
Ropero AB, Alonso-Magdalena P, Quesada I, Nadal A (2008) The role of estrogen receptors in the control of energy and glucose homeostasis. Steroids 73:874–879PubMedCrossRef
42.
Salpeter SR, Walsh JM, Ormiston TM et al (2006) Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8:538–554PubMedCrossRef
43.
Teede H, Deeks A, Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 8:41
44.
Sondheimer SJ (1991) Update on the metabolic effects of steroidal contraceptives. Endocrinol Metab Clin North Am 20:911–923PubMed
Metadata
Title
Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can)
Authors
Martin Almquist
Dorthe Johansen
Tone Björge
Hanno Ulmer
Björn Lindkvist
Tanja Stocks
Göran Hallmans
Anders Engeland
Kilian Rapp
Håkan Jonsson
Randi Selmer
Guenter Diem
Christel Häggström
Steinar Tretli
Pär Stattin
Jonas Manjer
Publication date
01-05-2011
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 5/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9747-2

Other articles of this Issue 5/2011

Cancer Causes & Control 5/2011 Go to the issue

Original paper

Getting cancer prevalence right: using state cancer registry data to estimate cancer survivors

Original paper

Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women

Original paper

Dietary habits and gastric cancer risk in north-west Iran

Original paper

Brain tumors and hormonal factors: review of the epidemiological literature

Original paper

Oropharyngeal cancer incidence trends: diminishing racial disparities

Original paper

Relationship between height at diagnosis and bone tumours in young people: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits